Immunologic Factor
trastuzumab Audio
[ tras-too-zoo-mab ]
Brand Names:
Enhertu; Herceptin; Herceptin Hylecta; Herzuma; KADCYLA; Kanjinti; Ogivri; Ontruzant; Phesgo; Trazimera
Effect:
Increased Cellular Death; Increased Protein Breakdown
May Treat:
Breast Neoplasms; Gastrointestinal Neoplasms
More Information:
ChemID; DrugBank; DailyMed; DrugInfo; PDR
Definitions related to trastuzumab:
  • A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
    NLM Medical Subject Headings
    U.S. National Library of Medicine, 2021
  • A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Trastuzumab is used to treat breast cancer that is HER2-positive and has spread after treatment with other drugs. It is also used with other anticancer drugs to treat HER2-positive breast cancer after surgery. Trastuzumab is also being studied in the treatment of other types of cancer.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
  • A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.